PDS Biotechnology Corp（PDSB）财务数据PDSBPDS Biotechnology Corp

Evaluating the bottom line, PDS Biotechnology Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -543.97%, provide a clear picture of how effectively PDSB converts its operational activities into shareholder value.

In the context of the broader market, PDSB competes directly with industry leaders such as CTOR and PTHS. With a market capitalization of $115.96M, it holds a leading position in the sector. When comparing efficiency, PDSB's gross margin of N/A stands against CTOR's 67.07% and PTHS's 70.18%. Such benchmarking helps identify whether PDS Biotechnology Corp is trading at a premium or discount relative to its financial performance.

PDSB has experienced substantial recent performance with a year-to-date change of +65.63% and a one-year change of +44.38%. However, it has reported negative net income for multiple quarters, with the latest quarter showing a net loss of $7,349,056.